Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of California, Davis
Eli Lilly and Company
Tizona Therapeutics, Inc
Essen Biotech
BicycleTx Limited
Mayo Clinic
Merck Sharp & Dohme LLC
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Seagen Inc.
University of Pittsburgh
Mayo Clinic
Merck Sharp & Dohme LLC
BicycleTx Limited
Jonsson Comprehensive Cancer Center
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Rondo Therapeutics
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
University of Washington
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
Trishula Therapeutics, Inc.
Emory University
Trishula Therapeutics, Inc.
Aprea Therapeutics
Hoosier Cancer Research Network
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Sotio Biotech Inc.
Carisma Therapeutics Inc
University of Utah
Merck Sharp & Dohme LLC
Southern Illinois University
Eli Lilly and Company
Northwestern University
M.D. Anderson Cancer Center
ADC Therapeutics S.A.
Sumitomo Pharma America, Inc.